drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Allogeneic CD19-directed CAR-γδ T-cell therapy; engineered gamma delta T cells expressing an anti-CD19 chimeric antigen receptor to mediate MHC-independent cytotoxic killing of malignant B cells in relapsed/refractory B-ALL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic gamma delta T cells engineered to express an anti-CD19 chimeric antigen receptor bind CD19 on malignant B cells and induce MHC-independent activation and cytotoxic killing (perforin/granzyme), aiming to eliminate relapsed/refractory B-ALL with reduced GVHD risk.
drug_name
QH103 Cell Injection
nct_id_drug_ref
NCT06056752